Ameriprise’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Ameriprise’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,910	Closed	-$312K	–	4036
2023 Q1	$312K	Buy	2,910 +165	+6%	+$19K	﹤0.01%	3602
2022 Q4	$302K	Buy	+2,745	New	+$178K	﹤0.01%	3584

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Ameriprise's RXDX Position: Q2 2023 in Review

Ameriprise sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,910 shares — an estimated $312K sold.

Ameriprise first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $312K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Ameriprise reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ameriprise sold 2,910 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $312K.
Ameriprise first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Ameriprise's Prometheus Biosciences, Inc. Common Stock position peaked at $312K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.